Technical Analysis for CYCN - Cyclerion Therapeutics, Inc.

Grade Last Price % Change Price Change
grade D 10.76 10.02% 0.98
CYCN closed up 10.02 percent on Monday, June 17, 2019, on approximately normal volume. The bears made the stock sink to a new 52-week low. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
0 Watchers
View Intraday Alerts Watchlist Portfolio

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong N/A Down Up
See historical CYCN trend table...

Date Alert Name Type % Chg
1,2,3 Retracement Bearish Bearish Swing Setup 0.00%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
Bullish Engulfing Bullish 0.00%
New 52 Week Low Weakness 0.00%
Multiple of Ten Bullish Other 0.00%
Outside Day Range Expansion 0.00%
Wide Bands Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
Multiple of Ten Bearish Other 10.02%
Inside Day Range Contraction 10.02%

Older signals for CYCN ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Get Started for Free!
Configure default chart indicators
Basic chart:
Profile
Cyclerion Therapeutics is a clinical-stage biopharmaceutical company harnessing the power of sGC pharmacology to discover, develop and commercialize breakthrough treatments for serious and orphan diseases. Cyclerion plans to advance its current portfolio of five differentiated sGC stimulator programs with distinct pharmacologic and biodistribution properties that are uniquely designed to target tissues of greatest relevance to the diseases they are intended to treat. These programs, each of which have important milestones in 2019, include olinciguat in Phase 2 development for sickle cell disease, praliciguat in Phase 2 trials for heart failure with preserved ejection fraction (HFpEF) and for diabetic nephropathy, IW-6463 in Phase 1 development for serious and orphan central nervous system diseases, and two late-stage discovery programs targeting serious liver and lung diseases, respectively.
Medicine Biopharmaceutical Medical Specialties Diseases Organ Systems Heart Failure Kidney Diseases Diabetic Nephropathy Cardiomyopathy Sickle Cell Disease
Is CYCN a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Recent News
Date Title
Jun 12 The Daily Biotech Pulse: Nuvectra Files For Expanded Label For Algovita SCS, Axovant Earnings, FDA Nod For Aratana
Jun 11 Cyclerion Therapeutics to Present Preclinical Data on its Clinical-Stage sGC Stimulators for Neurodegenerative and Cardiometabolic Diseases at the 9th International Conference on cGMP
Jun 11 The Daily Biotech Pulse: Lilly Reports Positive Long-Term Efficacy Data For Psoriasis Drug, Provention Bio Offering
Jun 6 The Daily Biotech Pulse: Takeda Pulls Plug On Amyloidosis Drug Trial, Chiasma Preps For Drug Launch With New CEO Appointment, Orchard Prices Offering
Jun 5 Ironwood Initiates Dosing in Mid-Stage Study for MD-7246
Jun 4 3 Spinoff Stocks Worth Your Attention
Jun 4 Cyclerion Therapeutics to Present Data on its Sickle Cell Disease Program at Upcoming Medical and Scientific Meetings
Jun 3 Healthcare and Tech dominate midday movers
May 13 Cyclerion Therapeutics Provides a Corporate and Pipeline Overview as a Newly Launched Public Biopharmaceutical Company
May 9 Cyclerion Therapeutics: This Spinoff Has Multiple Readouts Coming Up, Concerns Remain
See more CYCN news...
Indicators
Indicator Value
52 Week High 21.0
52 Week Low 9.06
Average Volume 184,727
200-Day Moving Average 0.0
50-Day Moving Average 14.5204
20-Day Moving Average 12.2985
10-Day Moving Average 10.267
Average True Range 1.3402
ADX 36.05
+DI 9.4993
-DI 22.3235
Chandelier Exit (Long, 3 ATRs ) 11.7094
Chandelier Exit (Short, 3 ATRs ) 13.0806
Upper Bollinger Band 16.7712
Lower Bollinger Band 7.8258
Percent B (%b) 0.33
BandWidth 72.735699
MACD Line -1.4763
MACD Signal Line -1.3725
MACD Histogram -0.1038
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 13.36
Resistance 3 (R3) 13.08 11.93 12.92
Resistance 2 (R2) 11.93 11.27 12.07 12.78
Resistance 1 (R1) 11.35 10.86 11.64 11.63 12.63
Pivot Point 10.20 10.20 10.35 10.34 10.20
Support 1 (S1) 9.62 9.54 9.91 9.90 8.89
Support 2 (S2) 8.47 9.13 8.61 8.74
Support 3 (S3) 7.89 8.47 8.60
Support 4 (S4) 8.17